[Drug therapy's new options in the treatment of the severe irritable bowel syndrome].

A A Viaznikova I N Ruchkina G M Diukova N V Romashkina L K Indejkina D A Degterev A I Parfenov

Published in: Terapevticheskii arkhiv (2023)

The severe course of IBS-D is mainly associated with the patients' individual characteristics and anxiety or anxiety-depressive syndromes. The positive impact of duloxetine therapy in severe IBS-D with extraintestinal manifestations is associated with the regulation of serotonergic and noradrenergic activity of the central.

Keyphrases

irritable bowel syndrome
end stage renal disease
early onset
ejection fraction
chronic kidney disease
drug induced
newly diagnosed
sleep quality
peritoneal dialysis
prognostic factors
bipolar disorder
depressive symptoms
bone marrow
combination therapy